Stockholder Notice: Robbins LLP Informs Investors of the Atara Biotherapeutics, Inc. Class Action Lawsuit

Core Viewpoint - A class action lawsuit has been filed against Atara Biotherapeutics, Inc. for allegedly misleading investors regarding its drug candidate tabelecleucel, which has faced regulatory challenges from the FDA [1][2]. Group 1: Allegations and Issues - The lawsuit claims that Atara failed to disclose significant manufacturing issues and deficiencies in the ALLELE study, which made FDA approval of tabelecleucel unlikely [2]. - It is alleged that the company overstated the regulatory prospects of tabelecleucel, leading to a heightened risk of regulatory scrutiny and jeopardizing ongoing clinical trials [2]. - The complaint indicates that these undisclosed issues were likely to have a significant negative impact on Atara's business and financial condition, rendering public statements materially false and misleading [2]. Group 2: Stock Price Impact - Following the announcement of a Complete Response Letter (CRL) from the FDA on January 12, 2026, Atara's stock price dropped by $7.79 per share, or 56.99%, closing at $5.88 per share [3]. Group 3: Class Action Participation - Shareholders who wish to participate in the class action against Atara Biotherapeutics can contact Robbins LLP, with the option to serve as lead plaintiff or remain an absent class member [4].